Cardiovascular risk escalation with caloric excess: a prospective demonstration of the mechanics in healthy adults by Alok K Gupta et al.
Cardiovascular risk escalation with caloric excess:
a prospective demonstration of the mechanics in
healthy adults
Gupta et al.








Gupta et al. Cardiovascular Diabetology 2013, 12:23
http://www.cardiab.com/content/12/1/23ORIGINAL INVESTIGATION Open AccessCardiovascular risk escalation with caloric excess:
a prospective demonstration of the mechanics in
healthy adults
Alok K Gupta1*, William D Johnson3, Darcy Johannsen2 and Eric Ravussin2Abstract
Context: The link between weight gain and cardiovascular risk characterized with circadian blood pressure
variability [CBPV] and endothelial function [EF] is unexplored.
Objective: To prospectively demonstrate weight gain in healthy adults, increases body fat [BF], enlarges waist
circumference [WC], expands visceral adipose tissue [VAT], exacerbates systemic inflammation [sIF], worsens insulin
resistance [IR] and enhances functional cardiovascular disease [CVD] risk.
Design, setting and participants: Healthy men [n=11] and women [n=3] provided initial and eight-week post-
caloric excess anthropometric and fasting laboratory measures. Functional CVD risk assessments: CBPV and resting
EF were also obtained with 7-day automatic ambulatory BP monitoring and increased test finger peripheral arterial
tone [PAT] relative to control [reported as relative hyperemia index (RHI)], respectively.
Intervention: After determining individualized mean energy requirements for weight maintenance over 7-days,
each participant received a personalized over feeding prescription (1.4 times; 41% carbohydrate, 44% fat, and 15%
protein) for 8-weeks.
Results: mean (SEM). Participants increased body weight [BW; +7.4(0.1) kg]*, body mass index [BMI; +2.5(0.2) kg/m2]*,
BF [+2.0(0.01)%]*, WC [+8.2(1.0) cm]*, and VAT [+0.2(0.03) L]* and intrahepatic lipid [IHL + 0.0004(0.002) L] :*all p < 0.01.
Increased subcutaneous adipose cell size [+0.3(0.01) ρL; p = 0.02] accompanied significant sIF [hs-CRP + 0.4(0.09) mg/dL;
p = 0.04; leptin 6.63 ng/ml; p = 0.0008] and IR [fasting plasma glucose; [FPG] +7.0(0.6) mg/dL;p = 0.01, fasting insulin; [FI]
+5.7(1.4) uIU/ml; p = 0.001, HOMA-IR +1.6(0.5); p = 0.02]. Abn CBPV {systolic [+5.4(0.8); p = 0.002, diastolic [+1.7(0.1); p =
0.07 and pulse pressure [PP] [+3.5(0.4); p = 0.003 mm Hg} or elevated heart rate [HR] [+4.9(0.5) bpm; p = 0.003] ensued.
Resting RHI declined by 0.47(0.004) from initial 2.24(0.09) to 1.77(0.1); p = 0.001, indicating endothelial dysfunction [ED].
Conclusions: Controlled caloric excess in healthy human adults over only 8-weeks significantly increased BF, VAT,
sIF [hs-CRP], IR [FPG, FI, HOMA-IR] and functional CVD risk [measured as abnormal circadian blood pressure variability
and impaired resting endothelial function].
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weight or obese status [1,2], in ectopic locations [like the
visceral compartment, liver, muscle] is dysfunctional. The
secreted adipokines [including cytokines and chemokines]
which mediate auto, para and endocrine actions, alter the
dynamic homeostatic milieu to favour systemic inflamma-
tion, and often manifest dysglycemia, dyslipidemia, and/or
a loss of blood pressure control [3-6]. These early changes
clinically seen as prediabetes, premetabolic syndrome and/
or prehypertension, as many as 10-15 years in advance of
the chronic changes subsequently leading to a diagnosis of
noncommunicable diseases like diabetes mellitus and
hypertension [4,7]. The early increase in pro-inflammatory
and pro-coagulant factors, reactive oxygen species, dysgly-
cemia, dyslipidemia, and loss of blood pressure [BP] con-
trol, are functionally detectable as abnormal circadian
blood pressure variability [abnCBPV] and resting endothe-
lial dysfunction [rED] [8,9].
Asymptomatic overweight adults with prediabetes, [com-
pared to matched overweight adults with normal glucose],
manifest abnormal circadian blood pressure variability
[10]. Among asymptomatic obese adults only those with
prediabetes and highly exacerbated systemic inflammation,
[compared to matched obese with normal fasting glucose
and marginally elevated systemic inflammation], display
both abnormal circadian blood pressure variability and
resting endothelial dysfunction [8]. Prediabetes and prehy-
pertension in otherwise healthy adults singly, or together
[co-existing prediabetes and prehypertension] place the in-
dividual on a pathway with potential for accelerated cardio-
vascular adverse events, including sudden death [11-14].
These results led us to formulate our overall hypothesis
that caloric excess, even in the short term, results in ec-
topic adipose tissue deposition. The adipose tissue cells
enlarge, alter their adipokine secretion menu tipping the
pro-inflammatory and anti-inflammatory homeostatic bal-
ance in favour of inflammation [leading to altered gly-
cemia and lipidemia] and potentiating the elements of the
renin-angiotensin-aldosterone system [resulting in loss of
BP control]. This latent, but high cardiovascular risk is
clinically manifest as prediabetes and/or prehypertension
and functionally as abnormal circadian blood pressure
variability and resting endothelial dysfunction.
With a well designed experiment, the early relationship
between caloric over-loading [modelled after the usual
American diet], an increased systemic inflammation, fast-
ing plasma glucose and loss of blood pressure control was
elucidated in genetically permissible rats. We were able to
show that both systemic inflammation and glycemia influ-
ence circadian blood pressure variability. We were further
able to demonstrate that dysglycemia induces abnormal
circadian blood pressure variability [15].
This prospective study with baseline and eight-week-
post controlled caloric excess measurements tests ourhypothesis that significantly expanded visceral adipose tis-
sue [increased body mass index and waist circumference],
increases adipose cell size [signifying adipose tissue dys-
function], potentiates systemic inflammation [increased C
reactive protein, leptin] and worsens insulin resistance [ele-
vated fasting plasma glucose, fasting insulin, and Homeosta-
sis Model of Assessment-Insulin Resistance (HOMA-IR)] in
healthy adults. These changes are also accompanied by per-
sistent abnormal circadian blood pressure variability and
endothelial dysfunction, both of which are functional corre-
lates indicating enhanced cardiovascular risk.
Methods
Study design and population
The EAT [Fat Cell Size, Overfeeding and Ectopic Fat] study
was approved by the Pennington Biomedical Research
Center Institutional Review Board and all volunteers pro-
vided written informed consent at the first screening visit.
Participants ages 20–40 years with BMI 22.0–32.0 kg/m2
and no history of chronic disease [high blood pressure, dia-
betes, severe obesity, heart, kidney, liver or gastrointestinal
disease] were enrolled. These subjects were willing to par-
ticipate in an 8-week study that resulted in a 5 – 10%
weight gain, consume all meals at the Pennington Biomed-
ical Research Center and not change their usual level of
physical activity. This manuscript includes data for four-
teen [of a total of thirty five] subjects who consented for
additional 7-day ambulatory blood pressure monitoring
and resting endothelial function testing.
Study methods
The study methods are described in detail previous pub-
lications [8,10] and in the main paper which includes all
thirty five subjects from this study. A brief description of
the methods is as below.
Initial screening
Included anthropometric measures [height, weight: for
calculation of body mass index], cardiometabolic testing
[complete blood count, chemistry-15 panel included
lipid profile, hepatic and renal function measures],
serum insulin and preparation of the subjects for over-
feeding. An archived plasma sample was used at the end
of the study to measure markers of systemic pro-inflam-
matory [high sensitivity C reactive protein], leptin and
anti-inflammatory activity [adiponectin].
Over feeding A study dietitian discussed types and vol-
ume of food that were to be provided during the 8-week
overfeeding phase, along with the requirement for con-
suming all meals on-site, under direct supervision. A
typical meal was presented to give the potential subject
a visual impression of the type and volume of food to be
consumed.
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Comprised of the study physician performing due med-
ical diligence. A detailed medical history followed by a
complete physical examination, along with a review of
the cardiometabolic testing was performed by the med-
ical investigator. This screening visit also included repeat
fasting blood draw for cardiometabolic testing, urinalysis
and a pregnancy test [for females].
Run-in testing
After successful completion of both screening visits,
subjects were enrolled in the study and were scheduled
for a 2-week run-in period. The purpose of the run-in
phase was to determine baseline energy requirements
and perform baseline testing. Included [week 1 of run
in] were a weight-specific dose of doubly labeled water
to enable measurement of energy expenditure and activ-
ity monitor, along with a record of all food [solid and li-
quid] intake. Subjects were advised to eat normally, and
reported to Pennington Biomedical Research Center
[PBRC] every morning for a fasted metabolic weight
[after voiding and in a hospital gown].
Beginning on day 8 [week 2 of run-in], subjects were
provided all meals according to their estimated calorie
requirements. Breakfast and dinner were consumed
under supervision in the inpatient unit, while lunch was
packed to go. The diet consisted of 41% carbohydrate,
44% fat, and 15% protein. Participants were instructed to
eat all of the provided food and to record any additional
items consumed. Metabolic weight was obtained every
day prior to breakfast.Baseline and post overfeeding testing
To proceed to baseline or post overfeeding testing, parti-
cipants had to be in energy balance [± 0.5 kg] for 3 con-
secutive days. For the baseline and post-overfeeding
testing, participants remained on the PBRC inpatient
unit for 3 consecutive days, during which they com-
pleted the following tests.Metabolic chamber
Sedentary energy expenditure was measured over 23 hours
in a whole-room calorimeter.Subcutaneous adipose tissue biopsy
After exiting the chamber, under fasting conditions, partici-
pants underwent subcutaneous fat biopsy. Approximately
300 mg of subcutaneous adipose tissue was collected by
Bergstrom needle for measurement of fat cell size, followed
by an additional 1,000 mg of tissue collected by liposuc-
tion for numerous RNA, DNA, histology, and protein
measurements.Magnetic resonance imaging [MRI]
Total abdominal adipose tissue including visceral [VAT]
and subcutaneous [SAT] was measured using a 3.0 T scan-
ner [General Electric, Excite HD System, Milwaukee, WI].
Dual energy X-ray absorptiometry [DXA]
Whole-body percent fat was measured by DXA [Hologics
QDR 4500A; Hologics, Bedford, MA]. Fat mass [FM] and
fat-free mass [FFM] were calculated from the percent
body fat and measured metabolic body weight.
QuickScan
A quick direct measurement of the amount of fat, muscle,
and water in the body was obtained using a magnet.
1H Magnetic Resonance Spectroscopy [MRS] for ectopic
lipid
Lipid content of the soleus and anterior tibialis muscles
[intramyocellular lipid, IMCL] and liver [intrahepatic
lipid, IHL] were measured by 1H MRS using the Point
Resolved Spectroscopy [PRESS] box technique. Liver fat
was measured with a commercially built 1H body coil.
7-day ambulatory blood pressure monitoring and resting
endothelial function testing
This testing was performed during the week 2 of the
run-in period.
Blood pressure and heart rate measurement
An ambulatory blood pressure monitoring device [MortaraW
Ambulo 2400] for ambulatory use was attached to a BP
cuff to obtain BP and HR readings at 30-min intervals dur-
ing the day [6:30 AM to 9:30 PM] and 60-min intervals at
night [10 PM to 6 AM] while the participants went about
their activities [8,10]. Data were downloaded into the data-
base at the end of the 7-day recording span for a chrono-
biological analysis [8,10].
Endothelial function testing
Assessment of resting endothelial function was done with
the participant in a fasting state, after having avoided sti-
mulants [caffeine, tobacco, alcohol, exercise] for 12 hours,
at the same fixed clock hour [range 8-10 AM], using
the EndoPAT 2000 device manufactured by ITAMAR
MedicalW. This assessment technique has been previously
validated [16], has been used in numerous [>250] peer
reviewed publications [9,17,18] and has been in routine
use in our clinical core. Briefly: subjects coming in from
home, after an overnight fast and having avoided stimu-
lants for 12-hours, were placed in a supine position for
20 minutes in a quiet room before the test. A patented sin-
gle use finger sleeve was then placed on the index finger
of each hand to continuously measure peripheral arterial
tone. A blood pressure cuff applied to the upper arm of
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clude the brachial artery for 5 minutes. This was followed
by a rapid release. The dominant arm without any ma-
nipulation served as the control. The built in, validated
software integrated the data gathered from the finger
sleeves of the control (undisturbed) and the test arms
(during the baseline, occlusion and release phases), thus
providing the relative hyperemia index (RHI) for the test
arm. This flow mediated dilatation induced change in the
test arm, relative to the control arm, served as the meas-
ure for endothelial function and was expressed as relative
hyperemia index [RHI].
Overfeeding
Participants were allowed one day of recovery from
baseline testing prior to beginning overfeeding. Prior to
overfeeding, all participants completed a 2-week meas-
ure of free-living energy expenditure by doubly labeled
water (DLW). During the second week of DLW, partici-
pants were fed to energy balance with a diet consisting
of 60% carbohydrate, 25% fat, and 15% protein. Energy
requirements to maintain usual body weight were deter-
mined from the run-in period and calculated as the
7-day average of the number of kcals required for energy
balance and the 14-day number of kcals expended as
measured by doubly labeled water [DLW]. This number
was then multiplied by 1.4 to obtain the subject’s over-
feeding prescription, and this individual prescription was
maintained throughout all 56 days [i.e. there was no
ramp-up period or re-adjustment for body weight
changes]. All meals were prepared in the metabolic kit-
chen at PRBC using a validated five-day rotating menu.
The diet consisted of 41% carbohydrate, 44% fat, and
15% protein for all subjects. Participants were free-living
during the overfeeding period but were required to re-
port to PBRC three times per day, seven days per week
to consume their meals, which were directly supervised
by nursing staff to ensure that all foods were eaten. Dur-
ing the final days of the study prior to metabolic testing,
subjects were fed to energy balance with the same diet
composition (60% carbohydrate, 25% fat, and 15% pro-
tein) provided at baseline.
Post overfeeding testing
Subjects had to be weight stable at their new [highest]
body weight for 3 days [±0.5 kg] prior to beginning post-
overfeeding testing [average 3 to 5 days]. On day 56, the
number of kcals needed to maintain energy balance at
each subject’s new body weight was calculated according
to the equation used during the run-in period. For 3 days
following overfeeding [days 57 – 59] subjects reported
to PBRC as usual but were provided with their new en-
ergy balance diet, which consisted of 60% carbohydrate,
25% fat, and 15% protein. Once stable, participants wereadmitted to the inpatient unit for 3 days of post-testing,
which consisted of repeating all baseline tests. Subjects
were discharged from the unit with appointments to re-
turn for follow-up testing at 1, 3 and 6 months later [not
included in the present analysis].
Adipose tissue measurement: fat cell size
Adipocyte cell [AC] size was measured using methods
adapted from Hirsch and Gallian [19].
Statistical analyses
All data analyses were conducted using SAS version 9.3
[SAS Institute, Inc., Cary NC]. Categorical data were sum-
marized as counts and percentages whereas measurements
assessed on continuous scales were summarized as means
and standard errors. Statistical significance [p ≤ 0.05] of
changes observed after eight weeks of excess caloric intake
was evaluated using paired t-tests. Correlation coefficients
were calculated to assess pair-wise associations between
changes in response to excess caloric consumption.
Results
Demographic, anthropometric, body composition and
metabolic characteristics of the participants
All results are expressed as mean(SEM). These otherwise
healthy 14 participants, 3 women and 11 men, 6 African
American/8 Caucasians on average were 28.4(1.1) years
young, weighed 79.4(3.4) kg and had BMI of 25.6(0.07)
kg/m2. Their mean weight by QuickScan was 79.1(3.3) kg,
with 56.7(3.3) kg of lean mass and 15.3(1.8) kg of fat mass.
Their mean WC was 82.5(2.2) cm; women with mean 75.1
(3.3) cm and men with mean 84.6(2.3) cm, well within the
desirable range of <88 and <102 cm, respectively. They
exhibited mean 22.2(2.2)% body fat by a DXA assessment
with men having a lower mean at 18.7(1.4)% and women,
as is customary, having a considerably higher 34.91(1.03)%
fat. A subcutaneous AT biopsy revealed mean AC size of
0.596(0.09) ρL. Men displayed smaller [0.58(0.1) ρL] adi-
pose cells, compared to women [0.64(0.01) ρL].
A complete blood count, fasting serum chemistry in-
cluding hepatic functions [Alkaline phosphatase 52(4.6)
IU/L and Alanine transaminase (20(1.5) IU/L] and kid-
ney functions were all normal. They all had normal FPG
[90.6(1.7) mg/dL], FI [4.7(1.0) μU/ml] and insulin resist-
ance [HOMA-IR 1.06(0.22)]. Their fasting lipid profile
[mean Total-C 177(7.6), LDL-C 102(7.1), HDL-C 60(3.4)
and TG 75.1(9.7) mg/dL] indicated metabolic normality.
Clinical characteristics of the participants
All subjects were healthy as indicated by a complete
medical history [including past medical, surgical, social
and family history] and a comprehensive medical exam-
ination. This was performed by the study physician
(medical investigator). None of the participants were on
Table 1 Demographic, anthropometric, body
composition, laboratory and clinical characteristics of
participants at baseline
AGE (years) 28.3(1.12) hs CRP (mg/L) 1.2(0.26)
GENDER (M/F) 11M/3F Leptin (ng/ml) 13.0(16.1)
RACE (C/AA) 8C/6AA Adiponectin (μg/ml) 4.6(2.4)
BMI (kg/m2) 25.6(0.65) FPG (mg/dL) 90.6(1.72)
WC (cm) 82.5(2.15) FI (μU/ml) 4.7(0.99)
FAT MASS (kg) 15.3(1.81) HOMA-IR 1.1(0.22)
LEAN MASS (kg) 56.7(3.27) SBP (mm Hg) 110.6(2.5)
VAT (L) 0.5(0.18) DBP (mm Hg) 67.8(1.5)
IHL (L) 0.005(0.001) PP (mm Hg) 42.9(2.6)
ALT (IU/L) 20.1(1.53) HR (bpm) 70.3(2.3)
SAT CELL SIZE (ρL) 0.59(0.09) EF (RHI) 2.24(0.09)
MEAN(SEM), BMI Body Mass Index, WC Waist Circumference, VAT Visceral
Adipose Tissue, IHL Intrahepatic lipid, ALT Alanine transaminase, SAT
Subcutaneous Adipose Tissue, FPG Fasting Plasma Glucose, FI Fasting insulin,
HOMA-IR Homeostasis Model of Assessment-Insulin Resistance, SBP Sytolic
Blood Pressure, DBP Diastolic Blood Pressure, PP Pulse Pressure, HR Heart Rate,
EF Endothelial Function.
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conditions requiring chronic intake of prescription med-
ications. One, two and three participants had a family
history of coronary artery disease, diabetes mellitus and
hypertension, respectively. These subjects at their clinic
visit had a normal temperature [36.6(0.3)°C], resting BP
[116.8(8.5)/75.2(6.6) mm Hg], PP [41.6(3.8) mm Hg] and
HR [55.7(8.7) beats per minute]. The mean BP, PP and
HR by ABPM over 7-days were: SBP/DBP 110.7(2.5)/
67.8(1.6) mm Hg, PP 42.9(0.9) mm Hg and HR 70.3(2.3)
beats per minute. The resting EF, measured in the morn-
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Figure 1 Change in body composition.avoided stimulants [caffeine, tobacco, alcohol] for over
12 hours was RHI 2.24(0.09). Table 1 details demo-
graphic, anthropometric, body composition, laboratory
and clinical characteristics for the participants at baseline.
Cardiovascular disease risk
Traditional cardiovascular risk factors, both non-modifiable
[age, gender, heredity] and modifiable [obesity, cigarette
smoking, high blood pressure, diabetes, elevated serum
total cholesterol [Total-C], low high-density lipoprotein
cholesterol [HDL-C], high triglycerides [TG], glucose in-
tolerance, low to high-density lipoprotein cholesterol ratio]
were assessed. The 10 year CVD risk was calculated for
each participant using the National Cholesterol Education
Program, Adult Treatment Panel III criteria. This was
found to be <1% for each participant.
Post caloric excess anthropometric, body composition
measures
These healthy subjects during 8-weeks of over feeding on
average gained weight [+7.4(0.1) kg; p = 0.001], increased
body fat [+2(0.01)%; p = 0.001], fat mass [+4.5(0.2) kg;
p = 0.001], body mass index [+2.5(0.03) kg/m2; p = 0.001]
and waist circumference [+8.2(0.1) cm; p = 0.001]. The
increase in waist circumference +8.3(4.6) cm in women
and +8.2(2.3) cm in men, however, did not place the mean
for either group above the desirable range for the waist
circumference (>88 and 102 cm for women and men, re-
spectively]. On average visceral adipose tissue increased
[+0.25(0.03) L; p = 0.01], intramyocellular lipid measure-
ments decreased [-0.00061(-0.00023) L], but intra hepatic
lipid increased [+0.0042(0.0025) L]. Figure 1 details the
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Figure 2 Change in body adipose tissue distribution.
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On average subcutaneous adipose cell size increased sig-
nificantly from 0.596(0.91) to 0.919(0.1) ρL; p = 0.02.
Post caloric excess elevation in systemic inflammation
Systemic inflammation assessed by high sensitivity C re-
active protein [hs CRP], although still within the normal
range, increased significantly on average from 1.24(0.25)
to 1.6(0.45) mg/L. Another marker for systemic inflam-
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Figure 3 Change in systemic pro inflammation and glycemia.to 19.66 ng/ml; p = 0.0008. Non-specific markers for in-
flammation like the total white blood cell count and
serum uric acid levels, although marginally higher, did
not change significantly.
Post caloric excess glycemia, insulin resistance,
adiponectin, lipid profile and hepatic functions
Fasting glucose significantly increased by an average of
7.0 mg/dL [range +31 mg to -6 mg/dL; p = 0.02], analogous
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[HOMA-IR +1.6; range +8.0 to +0.2; p = 0.04]. Although
significant changes were not observed in the complete
blood count, fasting serum chemistry and adiponectin
[anti-inflammatory adipokine], significant increases in the
fasting lipid profile [Total-C +18.9(15.7), LDL-C +13.5
(12.5), HDL-C +5.3(6.7); p < 0.01] with the exception of
TG [+0.7(18.5) mg/dL] were noted. The biomarker for hep-
atic function increased significantly serum Alanine trans-
aminase (ALT) [32.9(17.4) IU/L; p = 0.01]. Figures 2 and 3
depict the changes in body adipose tissue distribution and
change in systemic pro inflammation and glycemia,
respectively.Post caloric excess clinical and circadian blood pressure
changes
The clinic visit temperature and means of resting blood
pressure did not change significantly [36.6(0.3)°C, SBP/
DBP 118.8(10.3)/74.4(7.4) mm Hg], but the mean resting
heart rate significantly increased from 55.7(8.6) to 66.3
(12.2) beats per minute, p = 0.02. The mean systolic and
diastolic blood pressure, pulse pressure and heart rate
measured by ambulatory blood pressure monitoring over
7-days, however, all exhibited significant increases. The
overall group mean systolic blood pressure, diastolic
blood pressure and pulse pressure increased +5.4(0.8);
p = 0.002, +1.9(0.1); p = 0.07, +3.5(0.4); p = 0.003 mm
Hg, respectively. There was also a significant increase in
heart rate +4.9(0.5); p = 0.003 beats per minute. There
were significant increases in individual post caloric ex-
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Figure 4 Change in functional cardiovascular risk.diastolic blood pressure (5 out of 14), pulse pressure (7 out
of 14) and heart rate (7 out of 14). Every participant (with
the exception of two) had one, or more than one (post cal-
oric excess over baseline) significant change in the above
circadian blood pressure variability measures.Post caloric excess endothelial function
The resting endothelial function measurement was per-
formed in 12 of the 14 volunteers. The resting endothelial
function declined with relative hyperemia index decreasing
from 2.24(0.35) to 1.77(0.36); p = 0.004 in 10 of the 12 sub-
jects. The remaining two subjects could not have their
baseline assessment due to equipment malfunction. Figure 4
illustrates the change in functional cardiovascular risk.Correlations
Body composition measures exhibited widely known and
established correlations. Body mass index was strongly
correlated with body weight [r = 0.93], while waist circum-
ference was correlated with both body weight [r = 0.50]
and body mass index [r = 0.61].
Circadian blood pressure variability measures were corre-
lated with each other. Mean diastolic blood pressure was
correlated with mean systolic blood pressure [r = 0.68].
Mean double amplitude of variability of diastolic blood
pressure was correlated with the analogous variability of
systolic blood pressure [r = 0.80] and pulse pressure was
correlated with 7-day mean heart rate [r = 0.51].
Body weight was correlated with 7-day mean heart rate
[r = 0.44], while body mass index was correlated with 7-day
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deviation of heart rate [-0.55].
Systemic pro inflammation was highly correlated with
7-day mean systolic blood pressure [r = 0.61], pulse pres-
sure [r = 0.58], body weight [r = 0.82] and body mass
index [r = 0.84].
Fasting glucose was correlated with standard deviation
of heart rate [r = 0.46] and subcutaneous adipose tissue
fat cell size [r = 0.46].
Total-C [r = 0.62], LDL-C [r = 0.45] and HDL-C [r = 0.55]
were correlated with standard deviation of heart rate.
Triglycerides were correlated with visceral adipose tis-
sue mass [r = 0.71]. Alanine transaminase was correlated
with 7-day mean heart rate [r = 0.74], standard deviation
of heart rate [r = 0.54] and visceral adipose tissue mass
[r = 0.48].
Endothelial function was negatively correlated with
mean fasting plasma glucose [r = -0.40], total-C [r = -0.55],
LDL-C [r = -0.57] and triglycerides [r = -0.51].
Discussion
All fourteen participants after eight weeks of caloric ex-
cess exhibited increase in weight ranging from 2.7 to
11.1 kg, with a mean gain of +7.4(2.5) kg. The mean gain
in fat which was 4.5 kg (range 3.0-6.3 kg), translated to
an increase of 2% in body fat (range -0.15-4.9%) and the
lean mass by 2.82 kg (range 0.8-4.4 kg). These changes
along with the increase in body mass index, waist cir-
cumference were all significant. The American Heart
Association uses body mass index for assessment of total
body adiposity and waist circumference as a marker for
abdominal body fat [20]. In a biracial sample of men and
women common anthropometric measures (including
body weight, waist circumference and body mass index)
were moderately or highly correlated with total body fat,
abdominal fat and cardiovascular disease risk factors
[21]. These indices have also been used in the discovery
of out of the normal range blood pressure in adults, and
both out of normal range blood pressure and lipids in
adolescents [22,23]. Waist circumference is a surrogate
measure for visceral adipose tissue which has clinical
utility as an independent predictor of all-cause mortality
[24]. But despite these strong correlations, gender and
race influences these interpretations [25,26]. Excess adi-
pose tissue in the visceral compartment has been asso-
ciated with increased CVD risk in large prospective
studies: the Framingham and the Jackson Heart studies
[27,28]. In the present study with the overall body
weight gain we were able to demonstrate a significant in-
crease in body fat [+2%] and visceral adipose tissue vol-
ume [+0.2(0.03) L]. The increase in visceral adipose
tissue far exceeded the increase in subcutaneous tissue
(103% vs 30%), indicating a preferential deposition in the
visceral compartment.Caloric excess, which results in body weight gain and
expansion of the visceral adipose tissue compartment, can
also initiate an obligatory adipose tissue remodeling [29].
The changes beginning with the initial expansion to mat-
uration of adipocytes, followed by the infiltration of
macrophages, onset of hypoxia, inflammation and devel-
opment of insulin resistance have been reviewed in ex-
quisite detail [30]. We elucidated a significantly increased
mean subcutaneous adipose cell size [+0.32 ρL] is these
participants subsequent to 8-weeks of caloric excess.
While this is not a direct measure of the visceral adipose
cell size, it is an indication of a mature subcutaneous adi-
pose cell, at capacity, with no additional room for storage.
Indeed the magnitude of increase in visceral adipose tissue
(103%) compared to the subcutaneous adipose tissue
(30%), attests to preferential deposition in the visceral
compartment. Since a mature large adipose tissue cell is
dysfunctional, and there is evidence of dysfunction attrib-
utable to the visceral adipose tissue, the increase in vis-
ceral adipose cell size could be inferred.
The adipocyte hyperplasia and hypertrophy which
contribute to adipose tissue expansion can also result in
visceral adipose tissue dysfunction [30]. The exacerbated
systemic inflammation in obesity often results in
increased insulin resistance [12,31]. Non-specific makers
for systemic inflammation: total white blood cell count
[+0.5 × 10^3] and serum uric acid [+0.06 mg/dL] con-
centrations were higher, but did not reach the level of
significance. Elevated uric acid levels among other things
are associated with increase in blood pressure [32]. We
demonstrated a significant increase in systemic inflam-
mation concomitant with a significant increase in hs
CRP [+0.4(0.09) mg/dL]. The serum levels of leptin were
higher [+6.64 ng/mL; p =0.0008], a further indication of
the potentiated systemic inflammation. Although post
caloric total adiponectin [+0.98 μg/mL] and high-mo-
lecular-weight adiponectin [+598.43 μg/mL] were higher,
they did not reach significance. This lack of significant
increase despite a significant increase in fat mass would
be indicative of adipose tissue dysfunction.
Caloric excess can also result in ectopic lipid deposition,
especially in the liver and muscle, the consequence of
which, among other things, is insulin resistance [33,34]. We
found that our baseline intramyocellular lipid measure-
ments compared to post caloric excess decreased, but intra-
hepatic lipid increased. These early reciprocal changes in
the muscle and the liver of otherwise healthy subjects may
be reflective of an adaptive increase in the oxidative cap-
acity of the muscles (thus deceasing intramyocellular lipid)
and the onset of hepatic insulin resistance [35,36]. There
was also a significant increase in alanine transaminase
concentration [+12.8(3.1) IU/L], an initial indicator
for a functional impairment of hepatic function with
non-alcoholic fatty liver disease [37]. We elucidated a
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fasting plasma glucose +7.0(0.6) mg/dL, fasting insulin +5.7
(1.4) uIU/ml and HOMA-IR +1.6(0.5).
Along with the increase in body weight, body fat, waist
circumference, visceral adipose tissue compartment, sub-
cutaneous adipose cell size, systemic inflammation and
insulin resistance, a loss of blood pressure control and
endothelial dysfunction ensued in these subjects. This is in
keeping with the abnormal circadian blood pressure vari-
ability and endothelial function being functional markers
for an adverse cardiometabolic milieu [8,10]. In lean indi-
viduals with normal blood pressure, an increase in insulin
levels abolished the nocturnal decrease in blood pressure
and dampened the heart rate variability [38]. Increasing
concentrations of serum insulin acutely enhance the gain
of arterial baroreflex input to the muscle sympathetic
nerve activity [39]. We elucidated a significant increase in
7-day mean systolic [+5.4(0.8)], diastolic [+1.7(0.1)] and
pulse [+3.5(0.4) mm Hg] pressures, as well as an elevation
of 7-day mean HR [+4.9(0.5) bpm].
Endothelium, a thin monolayer lining the inner surface
of the blood vessels, is a receptor-effector organ which is
responsive to both physical and chemical stimuli and
maintains homeostasis not only by autocrine, but also
paracrine and endocrine actions [40,41]. Endothelial dys-
function appears to be both an effect of increasing insulin
resistance and cause in the pathogenesis of hypertension
[42,43]. The activation of renin-angiotensin-aldosterone
system [RAAS] is being recognized as being an underlying
cause not only for hypertension, but also for insulin resist-
ance and dyslipidemia [44]. Although we do not provide
direct measurements, the demonstrated change in all
three cardiometabolic parameters [blood pressure, gly-
cemia and lipidemia] could be due to up regulation of adi-
pose tissue RAAS. Subjects exhibited a decline in relative
hyperemia index by 0.47(0.004) from initial 2.24(0.09) to
1.77(0.1), indicating endothelial dysfunction (impaired
flow-mediated peripheral arterial tone).
This prospective study in free living healthy adults
obtaining baseline and eight-week measurements validated
our hypothesis that controlled caloric excess increases
body fat mass, preferentially expands visceral adipose tis-
sue, induces adipose cell dysfunction, potentiates sys-
temic inflammation and worsens insulin resistance. These
changes were also accompanied by persistent abnormal
circadian blood pressure variability and endothelial dys-
function, both of which are functional correlates indicating
enhanced cardiovascular risk [8,9]. Increased fat mass, ele-
vated leptin concentration, stimulated hypothalamic sym-
pathetic nervous system activity, which was functionally
seen as abnormal circadian blood pressure variability and
elevated heart rate. Expanded visceral adipose tissue with
equivocal adiponectin change signified adipose tissue
dysfunction, which potentiated systemic inflammation,exacerbated insulin resistance and induced resting endo-
thelial dysfunction [9,12].
Interestingly, the three subjects who did not change
their adipose cell size, did not also exhibit an adverse
change in their glycemic indices. One of them did not de-
velop any loss of BP control, while the other two did not
exhibit endothelial dysfunction. In line with our overall
hypothesis, the measures for circadian blood pressure
variability correlated with systemic inflammation, which in
turn was highly correlated with body weight and body mass
index. This suggests that increased adiposity exacerbates
systemic inflammation and (although not measured, plaus-
ibly due to increased elements of the renin-angiotensin-al-
dosterone system) induces loss of BP control. Fasting
plasma glucose correlated with subcutaneous adipose tissue
cell size suggesting that increased adipose cell size leads
to insulin resistance. The correlation of serum triglyc-
erides and alanine transaminase with visceral adipose tissue
volume implicates dysglycemia and ectopic deposition of
intrahepatic fat, respectively, with visceral adipose tissue ac-
cumulation. Additionally, the negative correlation of en-
dothelial function with fasting plasma glucose, Total-C,
LDL-C and triglycerides, explains endothelial dysfunction
with dysglycemia and dyslipidemia.
Limitations
The absence of a free living control group followed over
eight weeks without caloric excess is a limitation with
this study. While weight gain accompanied with an alter-
ation in body composition occurs naturally during vari-
ous periods of life cycle [adolescence [45,46], freshman
year at college [47,48], the period after marriage in men
[49], pregnancy [50] and mid life in women [51,52], the
change in weight and body composition in free living
healthy adults over eight weeks is likely to be minimal.
The average weight gain in young adults over time
ranges from 0.2 to 0.8 kg per year [53-56]. In free living,
healthy adult participants in this study, [mean age of
28 years; range 22-36 years], the change in weight over
eight weeks for the control group would therefore be
small compared to the significant mean weight gain of
7.4 kg [p = 0.001] with caloric excess. Since all of the
assessments detailed are influenced to some degree by
weight gain, it is also unlikely they would depict a sig-
nificant change in the control group.
Conclusions
The major finding from this study is that the seemingly
benign changes resulting from a short period of con-
trolled overeating were all appropriately, uniformly and
significantly altered as hypothesized, equivocally elevating
cardiovascular risk of the participants. While these changes
in chronic disease states have been described piecemeal,
this is a comprehensive demonstration of the early changes
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ticipants. Although in small numbers, this is a first pro-
spective demonstration of the link between controlled
caloric excess and a resulting increase in body fat, visceral
adipose tissue mass, systemic inflammation, insulin resist-
ance, loss of blood pressure control and endothelial dys-
function in humans.
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